NCT00521248View on ClinicalTrials.gov

Buprenorphine for the Treatment of Neonatal Abstinence Syndrome

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

April 30, 2004

Primary Completion Date

January 31, 2010

Study Completion Date

January 31, 2010

Conditions
Neonatal Abstinence Syndrome
Interventions
DRUG

buprenorphine

sublingual buprenorphine administered every 8 hours, titrated to control of abstinence symptoms

DRUG

Oral morphine solution

0.4 mg/kg/day morphine every 4 hours

Trial Locations (1)

19107

Thomas Jefferson University Hospital, Philadelphia

All Listed Sponsors
collaborator

National Institute on Drug Abuse (NIDA)

NIH

lead

Thomas Jefferson University

OTHER

NCT00521248 - Buprenorphine for the Treatment of Neonatal Abstinence Syndrome | Biotech Hunter | Biotech Hunter